Prescribing and deprescribing sodium valproate: implications for pharmacy practice

Children exposed to valproate in utero are at a high risk of serious developmental disorders (30 –40% risk) and congenital malformations (10% risk). Valproate is now contraindicated in pregnancy for all indications, except for the treatment of epilepsy in the absence of a suitable alternative
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research